CDK2 and non-small cell lung carcinoma: Since cyclin/CDK complexes are responsible for cell cycle progression, we stimulated five NSCLC cell lines with selective inhibitors against CDK1, CDK2, and CDK4/6 to identify which kinases mediate SMAD2L phosphorylation [27].